Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 208295
Company: WATSON LABS TEVA

Products on ANDA 208295

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
ALVIMOPAN	ALVIMOPAN	12MG	CAPSULE;ORAL	Prescription	AB	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 208295

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
12/19/2019	ORIG-1	Approval		STANDARD	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208295Orig1s000ltr.pdf

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/08/2021	SUPPL-2	Labeling-Package Insert		Label is not available on this site.

Therapeutic Equivalents for ANDA 208295

ALVIMOPAN

CAPSULE;ORAL; 12MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
ALVIMOPAN	ALVIMOPAN	12MG	CAPSULE;ORAL	Prescription	No	AB	216843	PAR PHARM
ALVIMOPAN	ALVIMOPAN	12MG	CAPSULE;ORAL	Prescription	No	AB	208295	WATSON LABS TEVA
ENTEREG	ALVIMOPAN	12MG	CAPSULE;ORAL	Prescription	Yes	AB	021775	CUBIST PHARMS